Study of Coagulation Activation Markers and Pre Eclampsia
Information source: University Hospital, Lille
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pre Eclampsia
Phase: N/A
Status: Completed
Sponsored by: University Hospital, Lille Official(s) and/or principal investigator(s): VĂ©ronique Houfflin Debarge, PHD, Principal Investigator, Affiliation: Universituy Hospital Of Lille, France
Summary
The primary purpose of the trial is to evaluate coagulation activator markers in patients
with pre eclampsia compared to control (normal pregnancy) and to correlate these markers
with the severity of the pathology.
Clinical Details
Official title: Coagulation Activation Markers and Pre Eclampsia : Correlation With Complications
Study design: Observational Model: Case Control, Time Perspective: Prospective
Primary outcome: Endogenous thrombin potential
Secondary outcome: genotype-phenotype correlation (Polymorphism of prostacyclin-synthetase promoter CYP8A1In preeclampsia group : correlation between biological markers and severity of the disease evolution of endogenous thrombin potential in women with preeclampsia
Detailed description:
100 pre-eclamptic patients will be compared to 200 control patients (100 control matched on
gestational age at inclusion and 100 control matched on delivery mode (section).
Blood and urine samples will be collected at PE diagnosis, delivery and post partum.
Two axes will be considered:
1. Thrombography, or kinetic measurement of thrombin generation, by studying the coagulant
profile according to Hemker's method in CAT System (Calibrated Automated Thrombogram)
and by thromboelastogram in ROTEM technique (delocalized coagulation analyzer), in
parallel to specific activation markers (thrombin-antithrombin complex, fibrin
monomers).
2. The balance of prostacyclin/thromboxane A2 by using ELISA method for urine samples and
genotype-phenotype correlation (Polymorphism of prostacyclin-synthetase's promoter
CYP8A1).
Eligibility
Minimum age: 18 Years.
Maximum age: 50 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- 18 years old
- diagnosis of pre eclampsia
Exclusion Criteria:
- multiple pregnancy
- less than 18 year old
Locations and Contacts
University Hospital of Lille, Lille, Nord 59037, France
Additional Information
Starting date: May 2010
Last updated: December 17, 2014
|